Lena Boehme

Lena Boehme

Auto-generated profile, based on publicly available information

Lena Boehme

Department of Diagnostic Sciences, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cancer Cell
Verified
Journal Article
Open access
JOJose Orgaz
Jose Orgaz
ECEva Crosas-Molist
Eva Crosas-Molist
ASAmine Sadok
Amine Sadok
APAnna Perdrix-Rosell
Anna Perdrix-Rosell
OMOscar Maiques
Oscar Maiques
VSVictoria Sanz-Moreno
Victoria Sanz-Moreno
Despite substantial clinical benefit of targeted and immune checkpoint blockade-based therapies in melanoma, resistance inevitably develops. We show cytoskeletal remodeling and changes in expression and activity of ROCK-myosin II pathway during acquisition of resistance to MAPK inhibitors. MAPK regulates myosin II activity, but after initial therapy response, drug-resistant clones restore myosin II activity to increase survival. High ROCK-myosin II activity correlates with aggressiveness, identifying targeted therapy- and immunotherapy-resistant melanomas. Survival of resistant cells is myosin II dependent, regardless of the therapy. ROCK-myosin II ablation specifically kills resistant cells via intrinsic lethal reactive oxygen species and unresolved DNA damage and limits extrinsic myeloid and lymphoid immunosuppression. Efficacy of targeted therapies and immunotherapies can be improved by combination with ROCK inhibitors.

20 November 2024 in Nature
Verified
Journal Article
Open access
PDF file
NYNadav Yayon
Nadav Yayon
VKVeronika R. Kedlian
Veronika R. Kedlian
LBLena Boehme
Lena Boehme
CSChenqu Suo
Chenqu Suo
BWBrianna T. Wachter
Brianna T. Wachter
STSarah A. Teichmann
Sarah A. Teichmann
T cells develop from circulating precursor cells, which enter the thymus and migrate through specialized subcompartments that support their maturation and selection1. In humans, this process starts in early fetal development and is highly active until thymic involution in adolescence. To map the microanatomical underpinnings of this process in pre- and early postnatal stages, we established a quantitative morphological framework for the thymus—the Cortico-Medullary Axis—and used it to perform a spatially resolved analysis. Here, by applying this framework to a curated multimodal single-cell atlas, spatial transcriptomics and high-resolution multiplex imaging data, we demonstrate establishment of the lobular cytokine network, canonical thymocyte trajectories and thymic epithelial cell distributions by the beginning of the the second trimester of fetal development. We pinpoint tissue niches of thymic epithelial cell progenitors and distinct subtypes associated with Hassall’s corpuscles and identify divergence in the timing of medullary entry between CD4 and CD8 T cell lineages. These findings provide a basis for a detailed understanding of T lymphocyte development and are complemented with a holistic toolkit for cross-platform imaging data analysis, annotation and OrganAxis construction (TissueTag), which can be applied to any tissue.

18 February 2019 in eLife
Verified
Journal Article
Open access
AAAminah Ali
Aminah Ali
LBLena Boehme
Lena Boehme
GCGuillermo Carbajosa
Guillermo Carbajosa
VSVlad C Seitan
Vlad C Seitan
KSKerrin S Small
Kerrin S Small
AHAlan Hodgkinson
Alan Hodgkinson
Mitochondria play important roles in cellular processes and disease, yet little is known about how the transcriptional regime of the mitochondrial genome varies across individuals and tissues. By analyzing >11,000 RNA-sequencing libraries across 36 tissue/cell types, we find considerable variation in mitochondrial-encoded gene expression along the mitochondrial transcriptome, across tissues and between individuals, highlighting the importance of cell-type specific and post-transcriptional processes in shaping mitochondrial-encoded RNA levels. Using whole-genome genetic data we identify 64 nuclear loci associated with expression levels of 14 genes encoded in the mitochondrial genome, including missense variants within genes involved in mitochondrial function (TBRG4, MTPAP and LONP1), implicating genetic mechanisms that act in trans across the two genomes. We replicate ~21% of associations with independent tissue-matched datasets and find genetic variants linked to these nuclear loci that are associated with cardio-metabolic phenotypes and Vitiligo, supporting a potential role for variable mitochondrial-encoded gene expression in complex disease.

29 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBrooke C. Wilson
Brooke C. Wilson
LBLena Boehme
Lena Boehme
AAAmbra Annibali
Ambra Annibali
AHAlan Hodgkinson
Alan Hodgkinson
TCThomas S. Carroll
Thomas S. Carroll
VSVlad C. Seitan
Vlad C. Seitan
Zbtb11 is a conserved transcription factor mutated in families with hereditary intellectual disability. Its precise molecular and cellular functions are currently unknown, precluding our understanding of the aetiology of this disease. Using a combination of functional genomics, genetic and biochemical approaches, here we show that Zbtb11 plays essential roles in maintaining the homeostasis of mitochondrial function. Mechanistically, we find Zbtb11 facilitates the recruitment of nuclear respiratory factor 2 (NRF-2) to its target promoters, activating a subset of nuclear genes with roles in the biogenesis of respiratory complex I and the mitoribosome. Genetic inactivation of Zbtb11 resulted in a severe complex I assembly defect, impaired mitochondrial respiration, mitochondrial depolarisation, and ultimately proliferation arrest and cell death. Experimental modelling of the pathogenic human mutations showed these have a destabilising effect on the protein, resulting in reduced Zbtb11 dosage, downregulation of its target genes, and impaired complex I biogenesis. Our study establishes Zbtb11 as an essential mitochondrial regulator, improves our understanding of the transcriptional mechanisms of nuclear control over mitochondria, and may help to understand the aetiology of Zbtb11-associated intellectual disability.

26 January 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
KLKai Ling Liang
Kai Ling Liang
JRJuliette Roels
Juliette Roels
MLMarieke Lavaert
Marieke Lavaert
TPTom Putteman
Tom Putteman
LBLena Boehme
Lena Boehme
TTTom Taghon
Tom Taghon

25 June 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
OMOscar Maiques
Oscar Maiques
BFBruce Fanshawe
Bruce Fanshawe
ECEva Crosas-Molist
Eva Crosas-Molist
IRIrene Rodriguez-Hernandez
Irene Rodriguez-Hernandez
AVAlessia Volpe
Alessia Volpe
Gilbert FruhwirthGilbert Fruhwirth
Gilbert Fruhwirth
Background: Metastasis is a hallmark of cancer and responsible for most cancer deaths. Migrastatics were defined as drugs interfering with all modes of cancer cell invasion and thus cancers’ ability to metastasise. First anti-metastatic treatments have recently been approved.Methods: We used bioinformatic analyses of publicly available melanoma databases. Experimentally, we performed in vitro target validation (including 2.5D cell morphology analysis and mass spectrometric analysis of RhoA binding partners), developed a new traceable spontaneously metastasising murine melanoma model for in vivo validation, and employed histology (haematoxylin/eosin and phospho-myosin II staining) to confirm drug action in harvested tumour tissues.Results: Unbiased and targeted bioinformatic analyses identified the Rho kinase (ROCK)-myosin II pathway and its various components as potentially relevant targets in melanoma. In vitro validation demonstrated redundancy of several RhoGEFs upstream of RhoA and confirmed ROCK as a druggable target downstream of RhoA. The anti-metastatic effects of two ROCK inhibitors were demonstrated through in vivo melanoma metastasis tracking and inhibitor effects also confirmed ex vivo by digital pathology.Conclusions: We proposed a migrastatic drug development pipeline. As part of the pipeline, we provide a new traceable spontaneous melanoma metastasis model for in vivo quantification of metastasis and anti-metastatic effects by non-invasive imaging.